Quince Therapeutics, Inc. announced the appointment of Dr. Hassan Abolhassani to its Scientific Advisory Board (SAB). Dr. Abolhassani is an Assistant Professor of Clinical Immunology and Research Specialist at the Karolinska Institutet in Stockholm, Sweden, and is recognized as a highly cited scientific researcher in immunology.
Dr. Abolhassani's expertise includes immunodeficiency disorders and Ataxia-Telangiectasia (A-T), making him a valuable addition to Quince's SAB. He joins as the ninth member, contributing to a board comprised of leading experts in various relevant fields.
Dr. Mauro Magnani, Ph.D., Chair of Quince's SAB, stated that Dr. Abolhassani's unique insight will support the advancement of eDSP for A-T and the strategic expansion of the company's development pipeline into other potential immunological and autoimmune rare disease indications where chronic corticosteroid treatment is relevant.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.